

Corrigendum

Corrigendum to “Inositol(s) from Bench to Bedside in Endocrinology and Gynecology”

Vittorio Unfer,¹ John E. Nestler,² Zdravko A. Kamenov,³ Nikos Prapas,⁴ and Fabio Facchinetti⁵

¹*Department of Medical Sciences, IPUS-Institute of Higher Education, Chiasso, Switzerland*

²*Department of Medicine and Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA, USA*

³*Clinic of Endocrinology, Alexandrovska University Hospital, Medical University, Sofia, Bulgaria*

⁴*IAKENTRO, Infertility Treatment Center, Thessaloniki, Greece*

⁵*Mother-Infant Department, University of Modena and Reggio Emilia, Modena, Italy*

Correspondence should be addressed to Vittorio Unfer; vunfer@gmail.com

Received 20 November 2017; Accepted 27 November 2017; Published 28 December 2017

Copyright © 2017 Vittorio Unfer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the Editorial titled “Inositol(s) from Bench to Bedside in Endocrinology and Gynecology” [1], a “Conflicts of Interest” section should have been added as follows:

Conflicts of Interest

Vittorio Unfer, the lead guest editor of the special issue, is an employee of LO.LI. PHARMA SRL. This company markets products containing inositols. John E. Nestler has received travel expenses from LO.LI. PHARMA and SUN Pharmaceuticals. Zdravko A. Kamenov has received travel expenses from LO.LI PHARMA. Fabio Facchinetti has received travel expenses from LO.LI. PHARMA, SUN Pharmaceuticals, and Alkem Laboratories. Nikos Prapas has no interests to declare.

References

- [1] V. Unfer, J. E. Nestler, Z. A. Kamenov, N. Prapas, and F. Facchinetti, “Inositol(s) from bench to bedside in endocrinology and gynecology,” *International Journal of Endocrinology*, vol. 2017, Article ID 8515703, 2 pages, 2017.



Hindawi
Submit your manuscripts at
<https://www.hindawi.com>

